EBR Systems Posts Strong Q1 Growth as Wireless Cardiac Pacing Rollout Accelerates

The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( (AU:EBR) ).

EBR Systems reported strong commercial momentum in the first quarter of 2026, with WiSE System implants in 41 commercial patients, more than double the previous quarter, bringing total implants in the pilot and Limited Market Release phases to 71. The company expects preliminary unaudited Q1 revenue between US$2.25 million and US$2.36 million, highlighting growing physician experience, broader site readiness and ongoing work on reimbursement pathways to support wider uptake.

The Limited Market Release advanced with 16 new purchase agreements and 22 additional physicians trained, taking the total trained to 55 and reinforcing the company’s push toward broader adoption of its wireless pacing technology. EBR also maintained an active investor outreach program and implemented a 1-for-10 reverse stock split of its common stock, altering the CDI conversion ratio to 10:1 without changing individual ownership stakes and positioning the capital structure for the next phase of growth.

The most recent analyst rating on (AU:EBR) stock is a Sell with a A$0.56 price target. To see the full list of analyst forecasts on EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh stock, see the AU:EBR Stock Forecast page.

More about EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh

EBR Systems, Inc. is a medical device company that has developed the WiSE System, the world’s only wireless cardiac pacing device for treating heart failure. The company is focused on commercialising this technology through a limited market release, targeting specialised cardiac centres and training physicians to drive adoption in key reimbursement-supported markets.

Average Trading Volume: 542,285

Technical Sentiment Signal: Sell

Current Market Cap: A$276.9M

See more data about EBR stock on TipRanks’ Stock Analysis page.